Susceptibility of Candida spp. of clinical origin to lucknomycin, a new polyenic antibiotic

Lucknomycin is a new polyenic derivative antifungal agent obtained from a Streptomyces diastatochromogenes culture. The in vitro activity of the compound was tested against 403 strains of different Candida species of clinical origin by the Sabouraud Agar dilution method. The mean geometrical value o...

Full description

Saved in:
Bibliographic Details
Published inChemotherapy (Basel) Vol. 31; no. 3; p. 211
Main Authors Sousa, A S, Gómez-Criado, C, Baquero, F
Format Journal Article
LanguageEnglish
Published Switzerland 01.01.1985
Subjects
Anti-Bacterial Agents - pharmacology
Antifungal Agents - pharmacology
Candida - drug effects
Humans
Microbial Sensitivity Tests
Polyenes - pharmacology
Online AccessGet more information

Cover

More Information
Summary:Lucknomycin is a new polyenic derivative antifungal agent obtained from a Streptomyces diastatochromogenes culture. The in vitro activity of the compound was tested against 403 strains of different Candida species of clinical origin by the Sabouraud Agar dilution method. The mean geometrical value of the minimal inhibitory concentrations (MIC) for Candida albicans was 0.85 microgram/ml, 6 times lower than the corresponding value of nystatin (5.29 micrograms/ml) and very close to that of amphotericin B (0.56 microgram/ml). Lucknomycin was also 4-10 times more active than nystatin on other Candida species, with an MIC similar to those obtained with amphotericin B.
ISSN:0009-3157
DOI:10.1159/000238338